0 (0%)		08-07 15:03
Open: High: Volume: 0		Pre. Close: Low: Market Cap: 0(M)

Short term
Mid term
Targets	6-month :	25.71	1-year :	27.88
Resists	First :	22.01	Second :	23.87
Pivot price	21.98
Supports	First :	19.01	Second :	15.81
MAs	MA(5) :	21.6	MA(20) :	21.96
	MA(100) :	17.12	MA(250) :	25.44
MACD	MACD :	0.4	Signal :	0.7
%K %D	K(14,3) :	24.9	D(3) :	33.3
RSI	RSI(14): 51
52-week	High :	74.48	Low :	6.87

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ NGNE ] has closed above bottom band by 20.2%. Bollinger Bands are 65.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	21.84 - 21.97	21.97 - 22.07
Low:	20.7 - 20.87	20.87 - 20.99
Close:	21.23 - 21.48	21.48 - 21.65

Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.

Sun, 03 Aug 2025
What institutional investors are buying NGNE stock - Discover the fastest growing stocks today - Jammu Links News

Sun, 03 Aug 2025
How volatile is NGNE stock compared to the market - Unmatched market performance - Jammu Links News

Sun, 03 Aug 2025
How many analysts rate NGNE as a “Buy” - Discover investment plans that deliver results - Jammu Links News

Sun, 03 Aug 2025
What is the risk reward ratio of investing in NGNE stock - Discover hidden gems in the stock market - Jammu Links News

Sun, 03 Aug 2025
What drives NGNE stock price - Build wealth with long-term growth strategies - Jammu Links News

Sun, 03 Aug 2025
Should I hold or sell NGNE stock in 2025 - Capitalize on emerging market opportunities - Jammu Links News

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange:
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	14 (M)
Held by Insiders	3.23e+006 (%)
Held by Institutions	9.2 (%)
Shares Short	2,250 (K)
Shares Short P.Month	0 (K)

EPS	-8.655e+007
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-9 %
Return on Assets (ttm)	701.1 %
Return on Equity (ttm)	-22 %
Qtrly Rev. Growth	925000 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-4.47
Qtrly Earnings Growth	-4.4 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-70 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	2.55e+006
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.